Press Release

Morgan Lewis Represents Phathom Pharmaceuticals in Revenue Interest Financing Agreement

May 05, 2022

NEW YORK, May 5, 2022: Morgan Lewis advised Phathom Pharmaceuticals Inc. in a revenue interest financing agreement for $260 million in non-dilutive capital. The agreement provides for an upfront $100 million cash payment and an additional $160 million cash payment upon US Food and Drug Administration approval of Phathom’s investigational product, vonoprazan, for the treatment of erosive esophagitis.

Phathom is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases.

A Morgan Lewis team of partners Conor Larkin and Greg Hartker, and associates Matthew Riehle and Anjali Deshpande represented Phathom.

For more, read Phathom’s announcement.